Japanese Firms In Other Industries Enter Stem Cell Device Work
This article was originally published in PharmAsia News
Executive Summary
Two Japanese manufacturers not normally associated with drug making are making moves that could affect the industry. Kawasaki Heavy Industries and Sanyo Electric are entering the business of life sciences with devices aimed at enabling research and development of stem cells for regenerative medicine and drugs. Kawasaki is drawing on its robot technology to design cell-culturing systems, while Sanyo is designing gear it developed for refrigeration systems for use in environmental-control situations requiring sealed spaces. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.